AWHL - Aspira Women's Health Inc.


0.3499
0.030   8.545%

Share volume: 14,014
Last Updated: 03-27-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: -0.05%

PREVIOUS CLOSE
CHG
CHG%

$0.32
0.03
0.09%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
40%
Profitability 35%
Dept financing 43%
Liquidity 20%
Performance 50%
Company vs Stock growth
vs
Performance
5 Days
20.32%
1 Month
-0.03%
3 Months
-44.44%
6 Months
-32.71%
1 Year
257.04%
2 Year
257.04%
Key data
Stock price
$0.35
P/E Ratio 
0.00
DAY RANGE
$0.32 - $0.35
EPS 
-$0.29
52 WEEK RANGE
$0.02 - $0.71
52 WEEK CHANGE
$257.04
MARKET CAP 
17.475 M
YIELD 
N/A
SHARES OUTSTANDING 
42.656 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$20,266
AVERAGE 30 VOLUME 
$30,392
Company detail
CEO: Nicole Sandford
Region: US
Website: aspirawh.com
Employees: 110
IPO year: 2000
Issue type:
Market: OTCM
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Aspira Women's Health Inc. engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVAInherit tests to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of Gynecologic cancer.

Recent news